NewVac Signs License and Co-Development Agreement With Janssen to

NewVac Signs License and Co-Development Agreement With Janssen to

Filed under: drug treatment programs in san francisco

NewVac Signs License and Co-Development Agreement With Janssen to Advance Novel Drug for Treatment of Solid Tumors. SAN FRANCISCO, CA, Jan 08, 2013 (MARKETWIRE via COMTEX) — NewVac LLC (a ChemRar company, resident of the Skolkovo Innovation Center in …
Read more on MarketWatch (press release)

 

Keryx Biopharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare

Filed under: drug treatment programs in san francisco

The U.S.-based Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA …
Read more on Sacramento Bee

 

Onyx Pharmaceuticals Announces 2013 Updates and Reviews 2012

Filed under: drug treatment programs in san francisco

SOUTH SAN FRANCISCO, CA, Jan 07, 2013 (MARKETWIRE via COMTEX) — Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today reviewed 2012 accomplishments and announced several 2013 business updates, which the company discussed during its … In July 2012, the U.S …
Read more on MarketWatch (press release)

 

Orexigen Reports Progress on Resubmission of Contrave NDA; Intercept Begins

Filed under: drug treatment programs in san francisco

{nfg}Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, announced progress with the United States Food and Drug Administration (FDA) on a faster path to resubmission of the Contrave® … that …
Read more on Equities.com